The pharmaceutical landscape has undergone remarkable transformation over the past two decades, with India emerging as a pivotal player in global healthcare delivery. As the world’s largest supplier of generic medicines and third-largest pharmaceutical producer by volume, India’s pharmaceutical exports reached approximately $27.85 billion in FY 2023-24, marking a trajectory that positions the country as both a manufacturing powerhouse and a testing ground for balancing innovation incentives with public health imperatives.
This evolution reflects more than commercial success. India’s approach to pharmaceutical patents represents a distinctive model that challenges conventional wisdom about intellectual property protection, one that other developing nations are studying closely as they navigate similar tensions between rewarding innovation and ensuring access to essential medicines.
The Architecture of India’s Patent Framework
India’s current patent system emerged from a deliberate policy evolution. The 1970 Patent Act initially recognized only methods of drug production for patenting, with a protection period of seven years. This process-focused approach allowed domestic manufacturers to reverse-engineer patented drugs, creating a robust generic industry that became known worldwide for producing affordable medications.
The turning point came with India’s entry into the World Trade Organization and subsequent compliance with the Trade-Related Aspects of Intellectual Property Rights agreement. Post-WTO membership and TRIPS compliance, India transitioned to a dual system of process and product patents, extending protection to 20 years. This shift, mandated by international obligations, could have simply replicated Western patent regimes. Instead, India crafted amendments that preserved critical flexibilities for public health.
The crown jewel of these flexibilities is Section 3(d) of the Patents Act, a provision that has become both celebrated and controversial in international pharmaceutical circles. Section 3(d) prevents patenting new forms of known substances unless they significantly improve how well the substance works, establishing a higher threshold for pharmaceutical patents than exists in most developed countries.
This section specifically targets what critics call “evergreening” which is the practice where pharmaceutical companies make minor modifications to existing drugs and seek fresh patents, effectively extending monopoly periods beyond the standard twenty years. Section 3D of the Indian Patent Act is intended to prevent drug companies from evergreening their patents by making small changes to drug formulations to justify extending the term of the patent.
The Novartis Decision: Defining Efficacy
The constitutional validity and practical application of Section 3(d) were tested in the landmark Supreme Court case Novartis AG v. Union of India in 2013. Novartis sought patent protection for the beta crystalline form of imatinib mesylate, marketed as Gleevec, a leukemia medication. The company argued that this form offered a thirty percent increase in bioavailability compared to the earlier version.
The Supreme Court disagreed, establishing a crucial precedent. The Court concluded that Section 3(d) was specifically designed to be a higher standard for patentability, a second tier filter to prevent evergreening in the crucial field of pharmaceuticals. More significantly, the Court definitively interpreted “efficacy” for pharmaceutical purposes as meaning “therapeutic efficacy”, requiring evidence of improved clinical outcomes, not merely better physicochemical properties.
This interpretation set a demanding evidentiary standard. Improved bioavailability, stability, or manufacturing characteristics alone do not suffice. Patent applicants must demonstrate that modifications translate into measurable therapeutic benefits for patients. The ruling resonated far beyond India’s borders, with countries like Argentina, Bolivia, Colombia, Ecuador, Peru, and Venezuela subsequently adopting similar examination guidelines.
Export Performance and Global Integration
India’s patent framework has not hindered its pharmaceutical industry’s expansion. Rather, the generic manufacturing capability built under earlier policies has positioned India uniquely in global markets. India majorly exports drug formulations and biologicals, and these products contribute to about 75% of the total pharmaceutical exports, demonstrating sophisticated manufacturing capabilities beyond basic active pharmaceutical ingredients.
The scale of India’s pharmaceutical footprint is substantial. The country now supplies 20% of global demand, including 40% of the US’s generic drug needs and 25% of the United Kingdom market. These figures reflect not just volume but also quality assurance. India has surpassed the United States in Food and Drug Administration-registered manufacturing sites, boasting 752 FDA-approved, 2,050 WHO Good Manufacturing Practices-certified, and 286 European Directorate for the Quality of Medicines-approved plants as of 2024.
Regulatory compliance has improved markedly. US FDA Official Action Indicated instances dropped by 50% in the last decade and European Medicines Agency non-compliance cases fell by 27%. This enhanced compliance record strengthens India’s position in highly regulated markets, countering concerns that flexible patent standards might correlate with lax quality controls.
The export momentum continues accelerating. Recent data indicates that pharmaceutical exports reached over 30 billion dollars in Financial Year 2024-25, marking an increase of over 9 percent compared to nearly 27.5 billion dollars in Financial Year 2023-24. The United States remains the dominant market, though India has successfully diversified into emerging economies across Africa, Latin America, and Southeast Asia.
Balancing Innovation and Access
Critics of Section 3(d) argue it discourages pharmaceutical research and development by reducing patent protections. The empirical record presents a more nuanced picture. Among a sample of 166 companies, only 37 were major R&D spenders, increasing steadily from 3.89 percent in 2001 to 8.35 percent in 2005/06, while the rest maintained their R&D expenditure around 1 percent. This suggests that factors beyond patent strength include market size, regulatory environment, and human capital and influence innovation investments.
Meanwhile, the public health benefits of India’s approach are substantial. The country serves as pharmacy to developing nations with limited healthcare budgets. Generic manufacturers in India supply affordable versions of essential medicines for HIV/AIDS, tuberculosis, malaria, and other diseases that disproportionately affect low-income populations. Organizations like Médecins Sans Frontières have repeatedly highlighted India’s role in enabling treatment programs that would be financially unsustainable with originator drug pricing.
The tension between access and innovation incentives remains real. Pharmaceutical research requires enormous capital investment with high failure rates. Companies reasonably argue they need robust patent protection to justify these risks. Yet the social costs of excessive protection, including preventable deaths and suffering when life-saving medications remain unaffordable and carry equal weight in policy calculations.
India’s approach attempts threading this needle through TRIPS flexibilities. Beyond Section 3(d), the Patents Act includes provisions for compulsory licensing, allowing generic production under specific circumstances when public health needs override patent holder interests. While rarely invoked, these provisions serve as backstop protections and bargaining leverage in drug price negotiations.
Recent Developments and Future Trajectory
The patent landscape continues evolving. The Government of India passed key legislative amendments to the Patents Rules, 2003, effective March 15, 2024, aiming to streamline patent prosecution and implement various court decisions. These amendments include simplified compliance requirements, with statements of patent working now filed once every three financial years rather than annually, reducing administrative burdens while maintaining transparency.
Judicial developments have further clarified patent boundaries. Recent High Court rulings have addressed product-by-process claims, establishing that such claims must represent genuinely novel and inventive products to merit protection. Courts have also strengthened procedural fairness requirements, mandating clear and reasoned objections from patent examiners, enhancing predictability for applicants.
Looking forward, India’s pharmaceutical sector faces both opportunities and challenges. The global patent cliff with numerous blockbuster drugs losing patent protection through 2030 creates substantial market opportunities for generic manufacturers. However, increased competition may compress margins, requiring efficiency improvements and value-added services.
The rise of biologics and biosimilars presents particular complexity. These complex molecules require different manufacturing approaches than small-molecule drugs, demanding significant capital investment and technical expertise. India has developed some capability in this space, though it lags innovator nations. How patent policy adapts to biologics, which involve different innovation dynamics than traditional pharmaceuticals, will significantly influence India’s future position.
Global Implications
India’s pharmaceutical patent journey offers lessons for other developing nations grappling with similar dilemmas. The country demonstrates that TRIPS-compliant patent systems can incorporate meaningful flexibilities protecting public health interests. Section 3(d)’s focus on therapeutic efficacy provides one model for preventing patent term extensions through minor modifications while still protecting genuine innovations.
That said, India’s approach emerges from specific historical, industrial, and institutional contexts not easily replicated elsewhere. The country’s established generic manufacturing base, large domestic market, technical expertise, and relatively sophisticated legal system all enabled this policy path. Smaller nations with less developed pharmaceutical sectors might find different balances more appropriate.
The pharmaceutical patent debate ultimately reflects competing values and interests. Innovation deserves reward and incentive. Simultaneously, access to essential medicines constitutes a fundamental health need, particularly in resource-constrained settings. No patent system perfectly balances these imperatives, and optimal policy likely varies across contexts.
India’s experience suggests that developing nations need not simply import patent frameworks designed for developed country contexts. Thoughtful use of TRIPS flexibilities, grounded in local needs and capabilities, can shape systems promoting both innovation and access. As India continues expanding its pharmaceutical footprint globally, its patent framework will face ongoing scrutiny and debate. The country’s ability to maintain this balance while scaling operations may prove as significant as the framework itself.
With pharmaceutical innovation entering new frontiers from personalized medicine to gene therapy, patent policy must continue adapting. India’s approach, emphasifzing therapeutic benefit over technical modification, provides one lens for evaluating patent applications in these emerging domains. Whether this standard proves workable for fundamentally novel treatment modalities remains to be seen.
What seems clear is that India has established itself not merely as a manufacturer but as a policy innovator in pharmaceutical intellectual property. Other nations watch this experiment closely, seeking insights for their own patent systems. In an era where pandemic preparedness and equitable healthcare access command increasing attention, India’s model offers one path forward including imperfect perhaps, but purposefully calibrated to serve both innovation and public health in an interconnected world.
Ishwarya Dhube is a third-year BBA LLB student who combines academic rigor with practical experience gained through multiple legal internships. Her work spans various areas of law, allowing her to develop a comprehensive understanding of legal practice. Ishwarya specializes in legal writing and analysis, bringing both business acumen and hands-on legal experience to her work.
* Views are personal
